Cleary Gottlieb is representing MSD Animal Health in its acquisition of the rights for Vecoxan from Elanco Animal Health Incorporated (Elanco) for $55 million.
The acquisition, which was signed on February 18, 2020, is in connection with Elanco’s continuing divestitures related to its agreement to acquire Bayer AG’s (Bayer) animal health business. The closing of the Vecoxan acquisition is contingent on Elanco closing its transaction with Bayer, as well as other customary closing conditions.
MSD Animal Health is the global animal health division of Merck & Co. Inc. It offers veterinarians, farmers, pet owners, and governments a wide range of veterinary pharmaceuticals, vaccines, and health management solutions and services.
Vecoxan is used for the prevention and treatment of coccidiosis in calves and lambs.
For more information, please see the press release here.